10.11.2015 • News

Court Says Mylan Can Uphold Perrigo Bid

A federal district court judge in New York has ruled that Mylan can continue its hostile takeover bid for Perrigo. In the case heard by the court, Perrigo claimed Mylan had made false statements by saying it expects the merged companies to see at least $800 million in pretax revenues by the end of the fourth year. However, Judge Naomi Reice Buchwald ruled that Mylan had conducted a “sound process” in devising the estimate.

Mylan has offered $75 in cash and 2.3 ordinary shares for each Perrigo ordinary share. As of September, the deal was valued at $27 billion. The Netherlands-headquartered drugmaker will be able to move forward with the acquisition if the majority of Perrigo shareholders tender their shares by Nov.13. Perrigo said it does not plan to appeal the ruling.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read